CUR - Neuralstem, Inc.
| Previous Close | 0.3600 |
| Open | 0.3560 |
| Bid | 0.3200 x 2200 |
| Ask | 0.4099 x 1200 |
| Day's Range | 0.3560 - 0.4195 |
| 52 Week Range | 0.2500 - 1.5900 |
| Volume | 798,119 |
| Avg. Volume | 205,056 |
| Market Cap | 7.607M |
| Beta (3Y Monthly) | 3.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•16 days ago
Germantown biopharma stock on the brink of delisting
Germantown-based Neuralstem Inc. (NASDAQ: CUR) has received notice that it could be delisted from the Nasdaq after failing to elevate its stock price consistently above $1 over the past six months. The stem cell therapy company received a letter May 29 that it will be delisted from the exchange, scheduled to take effect June 7, unless it requests a hearing by Wednesday afternoon before the Nasdaq Hearings Panel — which, the company reported in public filings, it intends to do. “At the hearing, the Company will present its plan to regain compliance with all applicable requirements for continued listing on Nasdaq, including the $1.00 bid price requirement, and request an extension within which to do so,” Neuralstem wrote in its filings.
- Simply Wall St.•2 months ago
Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Neuralstem, Inc. (NASDAQ:CUR) share pric...
- American City Business Journals•6 months ago
Germantown biotech faces stock delisting threat
Germantown-based Neuralstem Inc. has been put on notice that its stock could be delisted from the Nasdaq if the company can’t raise its share price above $1 continually within the next six months. The stem cell therapy company said it intends to continue actively monitoring its common stock price and will consider options to boost its value. To return to compliance, Neuralstem stock must close at or above $1 per share for at least 10 consecutive days, though the company could file for an extension or appeal.
- Simply Wall St.•7 months ago
How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?
Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...
- Simply Wall St.•9 months ago
Should You Have Neuralstem Inc’s (NASDAQ:CUR) In Your Portfolio?
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
- Benzinga•11 months ago
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
